Lindbrook Capital, LLC Mirati Therapeutics, Inc. Transaction History

Lindbrook Capital, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$41.99 - $62.38 $209 - $311	5 Added 2.53%	203 $11,000
Q3 2023 Oct 25, 2023	SELL	$27.8 - $45.35 $2,919 - $4,761	-105 Reduced 34.65%	198 $8,000
Q2 2023 Jul 28, 2023	BUY	$36.13 - $49.49 $2,890 - $3,959	80 Added 35.87%	303 $10,000
Q1 2023 Apr 26, 2023	BUY	$36.54 - $54.26 $4,786 - $7,108	131 Added 142.39%	223 $8,000
Q4 2022 Jan 24, 2023	SELL	$41.27 - $98.62 $3,260 - $7,790	-79 Reduced 46.2%	92 $0

Q3 2022 Nov 10, 2022	BUY	$59.5 - $86.7 $3,094 - $4,508	52 Added 43.7%	171 $12,000
Q2 2022 Aug 01, 2022	BUY	$39.16 - $88.71 $4,425 - $10,024	113 Added 1883.33%	119 $8,000
Q1 2022 Apr 21, 2022	SELL	$75.82 - $150.97 $1,061 - $2,113	-14 Reduced 70.0%	6 $0
Q4 2021 Jan 18, 2022	BUY	$132.01 - $190.29 $1,320 - $1,902	10 Added 100.0%	20 $3,000
Q3 2021 Nov 05, 2021	BUY	$132.13 - $177.45 $924 - $1,242	7 Added 233.33%	10 $2,000
Q2 2021 Jul 27, 2021	BUY	$144.0 - $179.73 $432 - $539	3 New	3 $0
Q1 2021 Apr 28, 2021	SELL	$158.92 - $221.61 $1,430 - $1,994	-9 Closed	0 $0
Q4 2020 Jan 27, 2021	BUY	$162.05 - $240.27 $1,458 - $2,162	9 New	9 $2,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.